Pan-Cancer Panel is a predesigned panel for targeted resequencing assay utilizing amplicon sequencing technology by Illumina system, designed to detect somatic variants and assessing tumor mutational burden (TMB) in tumor samples. The panel covers a total of 516 genes associated with major solid tumor types and maintains >96% correlation with whole exome datasets. CD Genomics utilizes targeted NGS sequencing technology to provide more efficient and accurate targeting of specific genes or mutations, and even to detect low frequency variations in cancer-associated genes. Targeted NGS sequencing facilitates sequencing of a large number of genes and samples in a single and cost-effective assay.
CD Genomics provides a pan-cancer panel sequencing and bioinformatics analysis for your cancer related researches.
(Check the Pan-Cancer Panel Sequencing Gene List for more genes.)
We provide customized bioinformatics analysis including:
CD Genomics provides the accurate and cost-effective pan-cancer panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for pan-cancer panel sequencing is outlined below.
For more information about the pan-cancer panel or need other amplification requirements, please contact us.